Bottom Fishing Penny Stocks / Small Caps with Charts

Find the bottoms and the tops will come. Charts are a graphical depiction of 'perceived' fundamentals. My chart interpretations are mine and I DO NOT give buy/sell recommendations. Do your own due diligence, I do. ** Riding The Winners 'Till They're Not **

You are not logged in.

#1 2020-12-07 21:29:48

Kush
Administrator

THRM - Therma Bright Inc

December 7, 2020
Therma Bright Achieves High Accuracy Results from Feasibility Studies for Its COVID-19 Rapid Saliva Test, CoviSafe(TM)

Toronto, Ontario--(Newsfile Corp. - December 7, 2020) -  Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce the preliminary results achieved during the feasibility studies indicate a test sensitivity of 80%  (correctly identifying positive cases) and a specificity of over 90% (correctly identifying negative results) for Therma's CoviSafe™ rapid test for detecting SARS-CoV-2 in saliva.

Therma entered into an agreement with nanoComposix, a developer and manufacturer of rapid diagnostic tests to perform feasibility studies with a short list of polypeptides identified by Therma's strategic partners. Preliminary studies have identified a number of polypeptide pairs that will be tested in the coming weeks in human saliva samples containing the SARS CoV-2 virus. (Has nanoComposix identified additional polypeptide pairs other than the one's that were initially supplied by Torion/Orpheus?)

It is expected that the performance (meaning the sensitivity of 80% and a specificity of over 90%) will be improved once the final pair of polypeptide reagents is optimized. The minimum standard for home-use approval of rapid antigen tests is 80% sensitivity with both FDA under Emergency Use Authorization ("EUA") and Health Canada under the Interim Order. Therma and its partners are pleased to have achieved the minimum threshold for approval as required by regulatory agencies.

In addition to the selection and optimization of the best polypeptide pair of reagents, nanoComposix will assist Therma and its partners in developing a proprietary test cartridge (If nanoComposix can procure the prototype test cartridges can they also become a supplier of the finished product since they know it inside/out.) and saliva collection device that will be cost effective, easy to use, secure and suited for routine home-use testing.

Therma will procure up to 300 prototype tests from one of its suppliers (high probability that they already have them) to undertake initial testing with selected sites in Ontario. The initial testing of the CoviSafe™ test will be for symptomatic patients. Therma is working with Public Health Ontario to identify sites in the Province to conduct preliminary testing and evaluation of CoviSafe™. (So the rumor was true big_smile big_smile. Since we have the highest number of cases in the country Ontario is the guinea pig. If proved up here, it will be a breeze getting fast tracked through HC) Testing is expected to start before year end, but because of potential delays due to the holidays, may extend into January.

As the CoviSafe™ test's performance is validated in symptomatic patients, it will be rolled out as a screening test for monitoring large populations of healthy individuals that are asymptomatic for illness. Therma Bright has received a request to perform the asymptomatic testing in the workplace with a national business with thousands of employees across Canada. (Potential partner???...) The goal is to provide our solution for routine and widespread testing at home, and in schools, workplaces, sporting events and other venues where a rapid result is required. (Implication might be that they have customers standing in line).

Once testing is complete and a minimum set with 300 samples data will be compiled and sent to both FDA and Health Canada for approval under EUA with FDA and the Interim Order with Health Canada. The Company expects to submit data to both regulatory agencies in early 2021. Therma Bright and its partners have initiated discussions with manufacturers of the test with a focus on scaling production on a commercial scale for worldwide distribution.
(Implication might be that the company will be filling orders no later than Feb/21.. LET THE PRE-ORDERS BEGIN..:D big_smile..)

Mr. Rob Fia, CEO of Therma Bright, commented: " We are extremely encouraged by the pace of development for our CoviSafe™ test and the interest and support received from potential users, particularly from Public Health Ontario. We are encouraged by the Province's desire to implement at-home COVID testing for asymptomatic, as well as symptomatic, subjects as soon as possible."

The Company also announces that pursuant to the Company's 10% rolling stock option plan and in compliance with the policies of the TSX Venture Exchange, it has granted incentive stock options to consultants of the Company to purchase up to an aggregate of 550,000 common shares of the Company. These options are exercisable for a period of 5 years at a price of $0.22 per share.

Therma Bright is not making any express or implied claims that its product, CoviSafe™, has the ability to eliminate or cure COVID-19 or the SARS-CoV-2 virus.

About nanoComposix:

nanoComposix provides nanoparticles, contract development services and scaled manufacturing to help our customers commercialize nanotechnology products in fields that include biodiagnostics, nanomedicine, and high-performance coatings. For additional information go to, www.nanocomposix.com

About Therma Bright Inc.

Therma Bright is a progressive medical device technology company focused on providing consumers and medical professionals with quality medical devices that address their medical and healthcare needs. The Company's initial breakthrough proprietary technology delivers effective, non-invasive and pain-free skincare. Therma Bright received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation of a variety of insect bites or stings. The Company received clearance for the above claims from the US FDA in 1997.

Therma Bright Inc. trades on the TSXV (TSXV: THRM) (OTC Pink: THRBF) (FSE: JNX). For more information visit: www.thermabright.com and www.coldsores.com

For further information, please contact:

Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com

THRMcorp.png
Click on the Image for Details

THRMrapid-Test.png
Click on the Image for Details

THRMrapid-Test.png

Please Note: The comments made are just that, comments and thoughts, not facts.

Offline

#2 2021-01-15 15:19:21

Kush
Administrator

Re: THRM - Therma Bright Inc

January 15, 2021

Therma Bright Adds Veteran Manufacturing Expert to Advisory Team to Advance its Saliva-Based Rapid Antigen Test CoviSafe™

Toronto, Ontario--(Newsfile Corp. - January 15, 2021) -  Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce the appointment of Ian Levine to the advisory board to assist with future scaling for the manufacture of CoviSafe™.

Mr. Levine will build the overall operations for the Therma Bright team to secure efficient and smooth delivery of CoviSafe™ to our global customers. Mr. Levine's experience in global manufacturing and distribution of regulated healthcare products will be instrumental in the final development of CoviSafe™ and the establishment of Therma Bright's manufacturing, logistics and distribution platforms for CoviSafe™.

Mr. Levine has over 22 years' experience as an entrepreneur in the healthcare and manufacturing industries. He has held roles as a senior executive reporting to board of directors and has taken numerous board member roles. Mr. Levine has experience building start-ups turning them into robust companies including one that became a successful $200M+ international company with over 280 employees across North America. Mr. Levine's skill set will be essential for the long-term growth of Therma Bright which includes organizational development; human resource management; research and development; product design; continuous product quality improvement; quality management and regulatory compliance; sales and marketing strategy; global sourcing; cultural diversification; operational excellence; and market positioning.

Mr. Levine is fluently bilingual in both official languages (English and French) and is an inventor of multiple global patents for medical devices. Mr. Levine holds a Bachelor of Science Degree in Anatomical Sciences and a Master's in Business Administration, both from McGill University.

Rob Fia, CEO & President commented:
"Therma Bright is pleased to add Ian Levine to our advisory team. Ian's experience in product design and development, scaling up manufacturing, quality management and distribution and marketing represents a significant addition to the Therma Bright team. Therma Bright is moving rapidly through R&D with CoviSafe™ as we prepare the path for regulatory submissions to the FDA, Health Canada, and to obtain the CE mark for Europe. Ian will work with manufacturers for CoviSafe™ with a focus on scaling commercial production for worldwide distribution once regulatory approval is achieved."

The Company also announces that pursuant to the Company's 10% rolling stock option plan and in compliance with the policies of the TSX Venture Exchange, it has granted incentive stock options to an officer of the Company to purchase up to 200,000 common shares of the Company. These options are exercisable for a period of 5 years at a price of $0.35 per share.

Therma Bright also announces that it has negotiated debt settlements with arm's length and non-arm's length creditors. Pursuant to the debt settlement agreements, and subject to acceptance by the TSX Venture Exchange, the Company has agreed to settle aggregate outstanding debt of $260,000 in consideration for which it will issue an aggregate of 866,664 common shares at a deemed price of $0.30 per share. Certain Insiders of the Company participated in the debt settlements (Joe Heng, Tim Peterson and Spencer Sungbum Huh, each a director of the Company, agreed to settle $20,000 debt owed to each of them for 66,666 shares each; and Victor Hugo, the Company's CFO, agreed to settle $10,000 debt for 33,333 shares). Participation by Insiders in the debt settlements is considered a "related party transaction" pursuant to MI 61-101. The Company is exempt from the requirements to obtain a formal valuation and minority shareholder approval in connection with the Insiders' participation in the debt settlements in reliance of sections 5.5(a) and 5.7(a) of MI 61-101, respectively, on the basis that participation in the debt settlements by the Insiders did not exceed 25% of the fair market value of the Company's market capitalization. All shares issued in relation to these debt settlements are subject to a hold period expiring four months + one day after the date the shares are issued, in accordance with applicable securities laws and the policies of the TSX Venture Exchange.

Therma Bright is not making any express or implied claims that its product, CoviSafe™, has the ability to eliminate or cure COVID-19 or the SARS-CoV-2 virus.

About Therma Bright Inc.
Therma Bright is a progressive medical device technology company focused on providing consumers and medical professionals with quality medical devices that address their medical and healthcare needs. The Company's initial breakthrough proprietary technology delivers effective, non-invasive and pain-free skincare. Therma Bright received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation of a variety of insect bites or stings. The Company received clearance for the above claims from the US FDA in 1997.

Therma Bright Inc. trades on the (TSXV: THRM) (OTC PINK: THRBF) (FSE: JNX). For more information visit: www.thermabright.com and www.coldsores.com

For further information, please contact:
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com

Follow us on Twitter

FORWARD LOOKING STATEMENTS

Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as development and commercialization of a rapid COVID-19 viral assay and related instrumentation, manufacturing PPE and hand sanitizers and applying for government grants to support the Company's future performance. as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether or not such results will be achieved. Actual results could differ materially from those anticipated due to a number of factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required under applicable securities regulations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

This press release is not an offer of the securities for sale in the United States. The securities have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an exemption from registration. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful.

Offline

#3 2021-02-04 20:56:10

Kush
Administrator

Re: THRM - Therma Bright Inc

January 18, 2021

Therma Bright Reports Improved Accuracy For Its COVID-19 Rapid Saliva Antigen Test, CoviSafeTM, And Prepares For Prospective Studies

Toronto, Ontario--(Newsfile Corp. - January 18, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that the most recent results achieved with nanoComposix using banked human saliva samples and utilizing a CoviSafe™ prototype device indicate a test sensitivity of 86% and a specificity of 100% for Therma's CoviSafe™ rapid antigen test for detecting SARS-CoV-2 virus in saliva.

As previously reported on December 7, 2020 preliminary results achieved during the feasibility studies indicated a test sensitivity of 80% and a specificity of over 90% for Therma's CoviSafe™. Therma is pleased to have achieved improved sensitivity and specificity with the CoviSafe™ prototype device.

This milestone now takes Therma Bright to the prospective clinical study phase which will be followed by regulatory approval applications.

Therma's CoviSafe™ prototype test showed an 86% sensitivity for samples with an RT_PCR Ct value below 30 and 100% sensitivity with Ct values of 25 or lower.

Ct or Cycle Threshold value indicates the number of times or cycles, that a DNA/RNA sample needs to be amplified for it to be detected by an RT-PCR test - the gold standard test for detecting COVID-19. The lower the Ct value, the higher the amount of viral RNA present in a sample, and the higher the Ct value, the lower the amount of viral RNA present in the sample. Current literature suggests that patients with Ct values below 30 are in the most infectious phase of the disease, so it is critical to identify these people as quickly as possible.

The minimum standard for home-use approval of rapid antigen tests is 80% sensitivity with both Health Canada under the Interim Order and the FDA under Emergency Use Authorization ("EUA"). The results achieved exceed the minimum threshold for approval with regulatory agencies.

Therma is in discussions with selected sites in Ontario, the US and international locations to conduct prospective studies with the optimized test. The initial testing of the CoviSafe™ prototype will be for both symptomatic and asymptomatic patients.

Therma has been working with Public Health Ontario, US partners, and international partners to identify sites for the prospective testing and evaluation of CoviSafe™.

Testing is expected to start upon approval from one of the study locations.

The initial prospective test will test a minimum of 100 CoviSafe™ prototype devices using fresh saliva from the study participants to gain feedback on how the test performs in a real-life setting.

This information will be used to improve the CoviSafe™ prototype at which time the final CoviSafe™ design will be locked.

The final locked CoviSafe™ design will be used for a minimum of a 300 person prospective study and the data obtained will be used for regulatory approval under the Interim Order with Health Canada and the EUA with FDA and to obtain the CE mark from Europe.

As previously announced on Jan 15, 2021, Mr. Ian Levine has been hired as an advisor to Therma Bright and is currently in the process of sourcing suitable suppliers and manufacturing partners to produce the test once it is approved.

Therma Bright and its partners have initiated discussions with manufacturers of the test with a focus on scaling production on a commercial scale for worldwide distribution. We are also exploring the feasibility of setting up new lateral flow assay manufacturing facilities in Ontario with the assistance of our financial partner.

The goal is to provide CoviSafe™ for routine and widespread testing of both symptomatic and asymptomatic individuals at home and in schools, workplaces, nursing homes, sporting events, airports and other venues where a rapid result is required.

Mr. Rob Fia, CEO of Therma Bright, commented:
"Therma Bright is working closely with nanoComposix and continues to make great strides to improve the performance of our CoviSafe™ test which we expect to optimize further with our partners. We are in discussions with multiple sites in in Ontario, the US and international locations who are pleased to assist Therma Bright with our prospective studies. We expect to report back to shareholders on our prospective testing in the near future."

Therma Bright is not making any express or implied claims that its product, CoviSafe™, has the ability to eliminate or cure COVID-19 or the SARS-CoV-2 virus.

About nanoComposix
nanoComposix provides nanoparticles, contract development services and scaled manufacturing to help our customers commercialize nanotechnology products in fields that include biodiagnostics, nanomedicine, and high-performance coatings. For additional information go to, www.nanocomposix.com

About Therma Bright Inc.
Therma Bright is a progressive medical device technology company focused on providing consumers and medical professionals with quality medical devices that address their medical and healthcare needs. The Company's initial breakthrough proprietary technology delivers effective, non-invasive and pain-free skincare. Therma Bright received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation of a variety of insect bites or stings. The Company received clearance for the above claims from the US FDA in 1997.

Therma Bright Inc. trades on the TSXV (TSXV: THRM) (OTC Pink: THRBF) (FSE: JNX). For more information visit: www.thermabright.com and www.coldsores.com

For further information, please contact:

Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com
PH: 1.844.274.6837

Follow us on Twitter

Offline

#4 2021-02-04 20:57:31

Kush
Administrator

Re: THRM - Therma Bright Inc

January 25, 2021

Therma Bright Acquires 100% Control of its COVID-19 Rapid Saliva Antigen Test and Announces Proposed Name Change for the Test

Toronto, Ontario--(Newsfile Corp. - January 25, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma Bright" or the "Company"), a progressive medical device technology company announces that it has taken 100% control of the research and development, regulatory, manufacturing and commercialization of its saliva-based rapid antigen test.

As a result, Therma Bright will retain 100% of all future revenue and profits from the sale of the saliva-based rapid antigen test.

Therma Bright previously announced on November 4, 2020, that it would retain 50% of the revenue and profit from the sale of its rapid antigen test through Torion Biosciences Inc. ("Torion").

Therma Bright will no longer pursue that arrangement with Torion Biosciences Inc., with 100% of the future economic benefit now flowing directly to Therma Bright Inc.

In addition, Therma Bright will create a new trademark name for its saliva-based rapid antigen test, temporarily called SCV2, until a new name is protected.

Corporate Updates:
Therma Bright is pleased to report that it is in advanced discussions with potential testing sites in multiple locations across Canada as well as sites in the United States and the United Kingdom.

Engaging in multiple locations will assist Therma Bright to achieve regulatory approvals in different jurisdictions such as CE in Europe and FDA and Health Canada approvals for North America.

Such regulatory approvals will allow for the roll out of the commercial test for multiple markets in the future. Therma Bright will now procure sufficient test kits to be used in the prospective studies to occur in the month of February.

Therma Bright is also in the process of identifying component suppliers to be used in the large-scale manufacturing of the SCV2 test and is identifying contract manufacturers to manufacture and assemble the final product.

Therma Bright also announces that it has negotiated debt settlements with arm's length creditors. Pursuant to the debt settlement agreements, and subject to acceptance by the TSX Venture Exchange, the Company has agreed to settle aggregate outstanding debt of $65,250 in consideration for which it will issue an aggregate of 145,000 common shares at a deemed price of $0.45 per share. All shares issued in relation to these debt settlements are subject to a hold period expiring four months + one day after the date the shares are issued, in accordance with applicable securities laws and the policies of the TSX Venture Exchange.

Rob Fia, CEO of Therma Bright commented: "This is a big win for us and our shareholders as we maintain 100% of the sales and profits of SCV2. Since our last press release on January 18th, 2021, announcing 86% sensitivity and 100% specificity, we are pleased to have received significant interest from overseas facilities in the UK, the US and in addition to the Province of Ontario, other provinces in Canada.

We will report back on the prospective study sites in the near future."

Therma Bright is not making any express or implied claims that its product, SCV2, has the ability to eliminate or cure COVID-19 (or SARS-CoV-2 virus).

About SCV2
SCV2 is a rapid antigen test developed as an at-home or point-of-need test that does not require lab instruments or specialized lab personnel to be performed. It can be administered by healthcare professionals or untrained users.

The test can help identify infected individuals in 15 minutes and is designed for at-home or point-of-need settings such as long-term care facilities, schools, or sporting events.

Studies have shown that an efficient at-home antigen test would significantly reduce virus transmission, specifically by asymptomatic and pre-symptomatic patients.

It would also allow individuals who receive negative tests to continue with their everyday activities, including work and school.

SCV2 takes advantage of a lateral flow technology to detect the presence of the COVID-19 virus in saliva. When complete, the SCV2 rapid screening test could be ideal for use in a variety of scenarios, such as:

  • As an at-home test and for monitoring

  • To identify if patients require further testing or treatment in a clinical setting

  • To verify if patients are ready for release from quarantine

  • To screen individuals prior to entering public venues such as airplanes, sporting events, religious gatherings, concerts and wedding events.

About Therma Bright Inc.
Therma Bright is a progressive medical device technology company focused on providing consumers and medical professionals with quality medical devices that address their medical and healthcare needs. The Company's initial breakthrough proprietary technology delivers effective, non-invasive and pain-free skincare. Therma Bright received a Class II medical device status from the FDA for its platform technology that is indicated to relieve the pain, itch, and inflammation of a variety of insect bites or stings. The Company received clearance for the above claims from the US FDA in 1997.

Therma Bright Inc. trades on the TSXV (TSXV: THRM) (FSE: JNX). For more information, visit: www.thermabright.com and www.coldsores.com

For further information, please contact:

Therma Bright
Rob Fia, CEO
rfia@thermabright.com

Offline

#5 2021-02-04 20:57:53

Kush
Administrator

Re: THRM - Therma Bright Inc

January 29, 2021

THERMA BRIGHT ADDS $1,171,875 TO TREASURY THROUGH EXERCISE OF WARRANTS AND OPTIONS

Toronto, Ontario--(Newsfile Corp. - January 29, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that in the past month, investors have exercised a total of 7,582,500 warrants and options to add $1,171,875 to the Company's treasury. With the addition of the $300,000, as previously reported in the press release on December 24th, 2020, the Company has added a total of $1,471,875 to the Company's treasury through the exercise of warrants and options in the last month.

These funds will be used to advance the development of the Company's COVID-19 saliva-based rapid antigen test, SCV2, and for general working capital.

About Therma Bright Inc.
Therma Bright is a progressive medical device technology company focused on providing consumers and medical professionals with quality medical devices that address their medical and healthcare needs. The Company's initial breakthrough proprietary technology delivers effective, non-invasive and pain-free skincare. Therma Bright received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation of a variety of insect bites or stings. The Company received clearance for the above claims from the US FDA in 1997.

Therma Bright Inc. trades on the TSXV: THRM, OTC MARKETS: THRBF, FRA:JNX. For more information visit: www.thermabright.com and www.coldsores.com

For further information, please contact:
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com

Follow us on Twitter.

Offline

#6 2021-02-26 11:27:54

Kush
Administrator

Re: THRM - Therma Bright Inc

February 26, 2021

THERMA BRIGHT ENTERS INTO CLINICAL TRIAL AGREEMENT FOR ITS AcuVid(TM) COVID-19 RAPID SALIVA-BASED ANTIGEN TEST

(Newsfile Corp.) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that it has entered into an agreement with a COVID-19 testing site located in the Greater Toronto Area to conduct a clinical study with the Company's AcuVid TM rapid antigen test for detecting SARS-CoV-2 virus in saliva.

The testing site is located within the Greater Toronto Area that has one of the highest positivity rates in Ontario. The positivity rate around the testing center is currently at 19%.

Due to the high positivity rate the Company expects to achieve the minimum number of positive samples required for regulatory approvals more quickly than other locations that were originally considered. Many of the original sites the Company was investigating for clinical trials have been experiencing lower positivity rates due to lockdowns across Canada which would have resulted in a greater expense to the Company along with longer testing periods to complete the clinical testing. The testing site will allow the Company to complete the clinical trial quickly followed by submission of the data to both the FDA and Health Canada.

With a clinical trial agreement signed, Therma Bright can seek Research Ethics Board (REB) approval and Health Canada approval for the proposed trial.

Once approval is received, the site will perform the AcuVid TM saliva test on 100 subjects followed by a minimum of 300 subjects.

The clinical trial is expected to start during the month of March.

Subjects at the COVID-19 testing site will provide nasal samples for the approved lab-based PCR COVID-19 test conducted by Public Health.

At the end of the trial, the results of the AcuVidTM saliva test and PCR test will be analyzed and submitted to the FDA and Health Canada as part of the regulatory applications and will also be used to apply for a CE mark in Europe.

Therma Bright is in discussions to complete additional clinical trials with the AcuVidTM rapid saliva-based antigen test in the US and other international locations.

Therma Bright is pleased to announce it has rebranded its diagnostic test line as AcuVidTM, which will be used for our existing COVID-19 test and any future related products.

The saliva antigen test, the AcuVid TM SARS-CoV-2 antigen test will be the first product as the Company is currently reviewing the addition of other COVID-19 diagnostic tests to create a range of diagnostic products.

Initial results for Therma's AcuVidTM showed an 86% sensitivity and 100% specificity, which provides Therma Bright with a high level of confidence that the study results will satisfy the regulatory agencies requirements for saliva-based antigen tests. The minimum standard for home-use approval of rapid antigen tests is 80% sensitivity with both Health Canada under the Interim Order and the FDA under Emergency Use Authorization ("EUA"). The results achieved exceed the minimum threshold for approval with regulatory agencies.

Discussions with component suppliers and manufacturing partners have progressed with a view to produce a minimum of 1 million tests per month initially with the ability to scale up as demand increases.

Therma Bright's goal is to provide a low-cost, scalable saliva-based test for routine and widespread testing of both symptomatic and asymptomatic individuals at home and in schools, workplaces, nursing homes, sporting events, airports and other venues where a rapid result is required. Initially the test will be used in controlled environments such as large companies, sports and music venues, nursing homes, airports, and schools where there is a health care worker or trained staff to assist with performing the test. As the regulations regarding home use become clearer and standardised, the test will be introduced as a home-use test.

Mr. Rob Fia, CEO of Therma Bright, commented:
"We are extremely pleased to have secured our first clinical test site in Ontario. Once we receive REB and Health Canada approval, the testing should be completed in short order at which point we will assemble our regulatory filing package and submit to the FDA and Health Canada. Recently, we have fielded many enquiries for our test from around the world. Our simple, easy-to-use saliva-based test is very attractive for high volume users who want a scalable low-cost solution to keep their companies operating, entertainment venues open and schools and nursing homes safe."

Therma Bright is not making any express or implied claims that its test product has the ability to eliminate or cure COVID-19 or the SARS-CoV-2 virus.

About Therma Bright Inc.
Therma Bright is a progressive medical device technology company focused on providing consumers and medical professionals with quality medical devices that address their medical and healthcare needs. The Company's initial breakthrough proprietary technology delivers effective, non-invasive and pain-free skincare. Therma Bright received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation of a variety of insect bites or stings. The Company received clearance for the above claims from the US FDA in 1997.

Therma Bright Inc. trades on the TSXV: THRM, OTCMARKETS: THRBF, FRA:JNX. For more information visit: www.thermabright.com and www.coldsores.com

For further information, please contact:
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com

Follow us on Twitter

FORWARD LOOKING STATEMENTS

Offline

Board footer

Powered by FluxBB

xxxx